Novomedix is a biotechnology company based in San Diego, CA, specializing in the development of innovative small molecule multi-pathway modulators for the treatment of cancer, fibrosis, and inflammatory diseases. With decades of drug development experience, Novomedix has established itself as a proven leader in the field, leveraging its expertise to target well-known hallmarks of disease and build a robust pipeline of therapeutic candidates.
Driven by a proprietary technology platform, Novomedix's novel therapies aim to modulate key pathways of cancer, fibrosis, and lung disease. Their lead candidate, NMX1, inhibits mTOR signaling and secretion of IL-11 to treat tumors while activating AMPK to protect the heart in TNBC. Additionally, the company is advancing several candidates designed to address fibrotic diseases, liquid tumors, and atopic dermatitis, all backed by compelling data in animal models and remarkable safety profiles.
Generated from the website